Assessment of SGLT2 Inhibitor, Canagliflozin Effects on Metabolic Syndrome-Induced Cardiovascular Disorders in Rats
Shamardl, H., Sadek, S., Ahmed, A. (2023). Assessment of SGLT2 Inhibitor, Canagliflozin Effects on Metabolic Syndrome-Induced Cardiovascular Disorders in Rats. EKB Journal Management System, 12(2), 84-94. doi: 10.21608/fumj.2023.323618
Hanan Shamardl; Sawsan Sadek; Amany Ahmed. "Assessment of SGLT2 Inhibitor, Canagliflozin Effects on Metabolic Syndrome-Induced Cardiovascular Disorders in Rats". EKB Journal Management System, 12, 2, 2023, 84-94. doi: 10.21608/fumj.2023.323618
Shamardl, H., Sadek, S., Ahmed, A. (2023). 'Assessment of SGLT2 Inhibitor, Canagliflozin Effects on Metabolic Syndrome-Induced Cardiovascular Disorders in Rats', EKB Journal Management System, 12(2), pp. 84-94. doi: 10.21608/fumj.2023.323618
Shamardl, H., Sadek, S., Ahmed, A. Assessment of SGLT2 Inhibitor, Canagliflozin Effects on Metabolic Syndrome-Induced Cardiovascular Disorders in Rats. EKB Journal Management System, 2023; 12(2): 84-94. doi: 10.21608/fumj.2023.323618